{
  "name": "Comparative Specifications of Major Genome Editing Tool Architectures",
  "description": "Comparative specifications of primary genome editing tool architectures and delivery modalities, compiled from peer-reviewed literature (Frontiers in Oncology / PMC7427626), technical reference guides, and regulatory standards from the FDA and NIST.",
  "page": "https://casrai.org/guides/what-is-a-gene-editing-tool",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-19T13:53:48Z",
  "temporalCoverage": "2020/2026",
  "spatialCoverage": "United States",
  "columns": [
    {
      "name": "Platform Architecture",
      "unit": "",
      "description": "Molecular class and designation of the genome editing system"
    },
    {
      "name": "Targeting Determinant",
      "unit": "",
      "description": "Molecular component governing DNA sequence recognition"
    },
    {
      "name": "Target Length",
      "unit": "nucleotides",
      "description": "Length of DNA target sequence recognized per active assembly"
    },
    {
      "name": "Cleavage Domain",
      "unit": "",
      "description": "Catalytic endonuclease structure responsible for phosphodiester bond cleavage"
    },
    {
      "name": "Cleavage Profile",
      "unit": "",
      "description": "Nature of DNA strand break generated at target locus"
    },
    {
      "name": "Sequence Constraint",
      "unit": "",
      "description": "Sequence requirement flanking the target locus"
    },
    {
      "name": "Primary Delivery Format",
      "unit": "",
      "description": "Predominant molecular format utilized for transient delivery in laboratory workflows"
    }
  ],
  "rows": [
    {
      "Platform Architecture": "CRISPR-SpCas9 (Class 2, Type II)",
      "Targeting Determinant": "Synthetic single-guide RNA (sgRNA)",
      "Target Length": 20,
      "Cleavage Domain": "RuvC and HNH nuclease domains",
      "Cleavage Profile": "Blunt double-strand break (3 bp upstream of PAM)",
      "Sequence Constraint": "5'-NGG-3' PAM motif",
      "Primary Delivery Format": "Ribonucleoprotein (RNP) complex"
    },
    {
      "Platform Architecture": "CRISPR-Cas12a / Cpf1 (Class 2, Type V)",
      "Targeting Determinant": "Single CRISPR RNA (crRNA)",
      "Target Length": 23,
      "Cleavage Domain": "Single RuvC-like nuclease domain",
      "Cleavage Profile": "Staggered 5-nt 5' overhang double-strand break",
      "Sequence Constraint": "5'-TTTV-3' PAM motif",
      "Primary Delivery Format": "Ribonucleoprotein (RNP) complex"
    },
    {
      "Platform Architecture": "TALENs (Transcription Activator-Like)",
      "Targeting Determinant": "TALE repeat domain tandem arrays",
      "Target Length": 36,
      "Cleavage Domain": "Dimeric catalytic domain of FokI endonuclease",
      "Cleavage Profile": "Staggered double-strand break within 12-20 bp spacer",
      "Sequence Constraint": "5' Thymidine preceding each TALE binding site",
      "Primary Delivery Format": "In vitro transcribed mRNA pair"
    },
    {
      "Platform Architecture": "Zinc Finger Nucleases (ZFNs)",
      "Targeting Determinant": "Tandem Cys2-His2 zinc finger protein domains",
      "Target Length": 24,
      "Cleavage Domain": "Dimeric catalytic domain of FokI endonuclease",
      "Cleavage Profile": "Staggered double-strand break within 5-7 bp spacer",
      "Sequence Constraint": "Specific triplet nucleotide binding without canonical PAM",
      "Primary Delivery Format": "Plasmid DNA or mRNA pair"
    },
    {
      "Platform Architecture": "Cytidine Base Editors (CBE)",
      "Targeting Determinant": "sgRNA-directed Cas9 nickase (nCas9)",
      "Target Length": 20,
      "Cleavage Domain": "Tethered cytidine deaminase (e.g. APOBEC1)",
      "Cleavage Profile": "Single-strand nick (C-to-T transition without DSB)",
      "Sequence Constraint": "5'-NGG-3' PAM motif",
      "Primary Delivery Format": "In vitro transcribed mRNA or RNP"
    },
    {
      "Platform Architecture": "Adenine Base Editors (ABE)",
      "Targeting Determinant": "sgRNA-directed Cas9 nickase (nCas9)",
      "Target Length": 20,
      "Cleavage Domain": "Tethered engineered adenine deaminase (TadA dimer)",
      "Cleavage Profile": "Single-strand nick (A-to-G transition without DSB)",
      "Sequence Constraint": "5'-NGG-3' PAM motif",
      "Primary Delivery Format": "In vitro transcribed mRNA or RNP"
    }
  ],
  "sources": [
    {
      "title": "CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427626/",
      "accessed": "2026-11-19"
    },
    {
      "title": "What are genome editing and CRISPR-Cas9?: MedlinePlus Genetics",
      "url": "https://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/",
      "accessed": "2026-11-19"
    },
    {
      "title": "NIST Genome Editing Consortium",
      "url": "https://www.nist.gov/programs-projects/nist-genome-editing-consortium",
      "accessed": "2026-11-19"
    },
    {
      "title": "Human Gene Therapy Products Incorporating Human Genome Editing",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing",
      "accessed": "2026-11-19"
    }
  ]
}